The burden of, and treatment for, fragility fractures are often described in quantitative terms; the number of people with fractures, days and cost of hospitalization, risk of fracture, bone density and other factors are well-known statistics of osteoporosis. The qualitative aspects of fractures may be less frequently described. Health-related quality of life (HR-QOL) is an important consideration to describe more completely the burden and treatments associated with osteoporosis. HR-QOL describes the extent to which fractures impact an individual's ability to function in his or her daily life and encompasses the patient's perceived physical, mental, and social well-being. The decrement in HR-QOL associated with osteoporosis is comparable to that of other chronic conditions including arthritis, chronic obstructive pulmonary disease, diabetes, and heart disease. The impact of fractures on HR-QOL can be measured with general health questionnaires or with osteoporosis-specific tools that may even be specific to the type of fracture. The Qualeffo-41 questionnaire is specific to patients with vertebral fractures and measures quality of life in five domains: pain, physical function, social function, general health perception, and mental function. Approximately 75% of patients with clinical vertebral fractures report chronic pain, which may result in a reduction in physical activity levels, potentially leading to other decrements in HR-QOL. The effect of osteoporosis treatments on HR-QOL in patients has been done infrequently. A recent review of patients treated with teriparatide found that they had a reduced risk of new or worsening back pain compared with patients treated with other therapies. The assessment of HR-QOL in patients with fractures is another dimension in the management of osteoporosis.
SY2. MAXIMIZING ADHERENCE TO OSTEOPOROSIS THERAPIES
Hanley DA; University of Calgary, Alberta, Canada
Osteoporosis is a systemic skeletal disease characterized by low bone mineral density and microarchitectural deterioration, resulting in an increased susceptibility to fracture. In recent years, clinical trials have established the efficacy of commonly used treatments including antiresorptive and bone formation agents when taken consistently for the duration of the study trial. The reduction in the risk of vertebral fractures ranges from 30-65% and nonvertebral fracture risk is reduced 16-53%. Prior to the time of the fracture, however, osteoporosis may be described as a ''clinically silent'' or asymptomatic disease because the patient is often unaware of the loss in bone density or changes in architecture. Consistent with other chronic, largely asymptomatic conditions, long-term adherence to prescribed medication is generally poor (Solomon et al., 2005 Archiv Intern Med). The challenge for the physician is to maximize adherence to treatment plans, to achieve the potential benefits of increasing bone mineral density and reducing the risk of new fractures.
Adherence consists of 2 components: persistence (taking the drug for the recommended time) and compliance (taking the drug as prescribed). Evidence suggests that approximately 50% of patients are not persistent with treatment after one year. Suboptimal compliance (<80%) is associated with suboptimal outcomes. Poor adherence to long-term medication use is reflected in lower gains in bone mineral density, less likelihood of achieving expected changes in markers of bone turnover, and lower reduction in risk of fracture. Barriers to adherence include side-effects, lack of acceptance that the treatment is needed or effective, and complex or inconvenient dosing regimens. Strategies to maximize compliance may include patient education regarding the disease state and appropriate guidelines for drug use, demonstrating treatment response based on markers of bone turnover or bone mineral density, nurse monitoring, and more convenient dosing regimens. Fractures are the clinically significant outcome of osteoporosis. Since 1994, a diagnosis of osteoporosis could also be made using the World Health Organization (WHO) threshold of a bone mineral density (BMD) T-score below -2.5. Recent epidemiological studies, however, found that approximately half of incident fragility fractures occur in postmenopausal women with a T-score above -2.5. Although osteoporosis therapies effectively reduce the risk of vertebral and nonvertebral fractures, an assessment of long-term fracture risk is needed to identify the greatest number of patients who may benefit from osteoporosis therapy. Over the past few years epidemiologic studies and national registries have provided information about the incidence of nonvertebral fractures in several regions of Europe. Studies have also provided information about risk factors for fracture as well as the cost of caring for fractures patients and the change in quality of life resulting from a fracture.
SY3. FUTURE DIRECTIONS IN OSTEOPOROSIS THERAPY: NONVERTEBRAL FRACTURE OUTCOMES AND LONG-TERM FRACTURE RISK ASSESSMENT
As part of the WHO initiative, the average 10-year probability of hip fracture as well as the major 4 clinical fractures (spine, hip, humerus and forearm) was recently reported.(Kanis et al., 2005 OI). Large randomized placebo-controlled trials of several osteoporosis treatments have been published that provide information about the effect of treatment on the risk of spine as well as hip and other non-spine fractures. Available data suggest that the reduction of hip fractures and of other nonvertebral non-hip fractures is in the same order of magnitude. Recently the Group for the Respect of Ethics and Excellence in Science (GREES) recommended that anti-fracture efficacy of osteoporosis therapies be demonstrated for major nonvertebral fractures and not the hip only (Reginster et al., 2006) . Therefore, the effect of treatment on the incidence of overall nonvertebral fractures appears to be a justified primary endpoint in the evaluation of new agents for treatment of osteoporosis. This new strategy does not preclude to analyze the specific effect of a new agent on hip fracture as a secondary endpoint. Long-term adherence with oral bisphosphonates is required for optimal and sustained therapeutic outcomes. However, adherence with daily and weekly administration schedules is suboptimal, with less than half of patients continuing treatment at 1 year. [1] [2] [3] For example, in a retrospective cohort study of the PHARMO database, only 43% of new bisphosphonate users (etidronate, alendronate or risedronate; n=2,124 in total) persisted with treatment to this time point. 3 Poor therapeutic adherence has a significant impact on treatment outcomes. Nonadherent patients fail to achieve optimal decreases in bone turnover 4 and increases in bone density 5 , and this ultimately leads to increased fracture risk.6 A 24-month, longitudinal cohort study of the Medstat MarketScant database (n=6,825 women with osteoporosis) found that noncompliant and nonpersistent patients were 1.25 and 1.33 times more likely to have an osteoporotic fracture than compliant and persistent patients, respectively. 6 Thus, non-compliant and non-persistent patients had a significant increase in fracture risk (p<0.001 and p=0.0069, respectively).
Understanding why one patient persists with treatment and another discontinues is essential when devising strategies to improve adherence. A five-country survey commissioned by the International Osteoporosis Foundation compared physician (primary or secondary care) and patient (lapsed or current bisphosphonate users) perspectives on issues surrounding therapeutic adherence. 7 While physicians (41%) often indicated that emphasizing risks and complications would encourage adherence, many (86%) were unsure as to how best to motivate their patients. Knowing they were helping themselves or preventing fractures was likely to motivate patients to continue with medication (27% and 15%, respectively). Patients and physicians agreed that reducing dosing frequency could improve the acceptability of, and adherence to, bisphosphonates.
Adherence with current oral bisphosphonates is suboptimal and compromises therapeutic outcomes. Tailoring treatment to meet patient expectations and optimizing the physician-patient relationship may help to improve adherence.
When assessing treatment options for postmenopausal osteoporosis, consideration of patient preferences can have a positive influence on therapeutic outcomes. With oral bisphosphonates, prospective studies demonstrate a strong patient preference for weekly over daily dosing. 1, 2 This advantage is associated with a significant improvement in long-term therapeutic adherence, although adherence still remains suboptimal. 3, 4 However, such positive experience with the weekly regimen suggests that further reducing dosing frequency may provide additional adherence benefits.
Ibandronate is a potent, nitrogen-containing bisphosphonate that can be administered as a once-monthly regimen. In a 6-month, two-period, open-label, cross-over, patient preference study conducted in the USA (BALTO I), naïve or lapsed bisphosphonate users with postmenopausal osteoporosis (n=342) were randomized to monthly ibandronate (150 mg) for 3 calendar months or weekly alendronate (70 mg) for 12 weeks before switching to the alternative treatment. 5 Self-completed patient questionnaires revealed that the majority of patients who expressed an opinion (93%) preferred monthly ibandronate to weekly alendronate (71.4% vs 28.6%, respectively; preference rate for monthly: p<0.0001) and found it more convenient (74.6% vs 25.4%, respectively; convenience rate for monthly: p<0.001). Monthly dosing was also considered easier to follow in the long term (61% vs 25%) and better suited to lifestyle (55% vs 21%). Overall safety profiles were comparable. A second study of identical design conducted in Europe and the USA (BALTO II) confirmed these findings.
Consideration of patient preferences for less frequent bisphosphonate dosing is likely to improve adherence. Ongoing studies are evaluating the impact of once-monthly ibandronate dosing on patient adherence.
Patients prefer less frequently dosed bisphosphonates. 1 However, for such regimens to be adopted, comparable efficacy and safety versus more frequent bisphosphonate regimens must be demonstrated.
Oral ibandronate has been extensively studied for daily and less frequent administration in postmenopausal osteoporosis. [2] [3] [4] [5] In BONE, a randomized, double-blind, placebo-controlled study, robust vertebral antifracture efficacy was obtained with daily ibandronate (2.5 mg; 3-year vertebral fracture risk reduction: 62%).
2 Although no effect was observed in the overall population, a significant reduction in nonvertebral fracture risk (69%) was reported in patients at higher risk for fracture (baseline femoral neck BMD T-score <-3). 'Proof of concept' for significant vertebral fracture risk reduction (50%) with a novel intermittent regimen (dosing interval >2 months) was also observed. Independent of the dosing schedule, similar and sizeable changes in bone remodeling and bone density were detected. Overall and upper gastrointestinal safety profiles were also comparable and similar to placebo.
Following successful preliminary evaluation, 2 a randomized, double-blind, noninferiority study (MOBILE) was initiated to establish the comparable efficacy of once-monthly (50+50 mg, 100 mg, 150 mg) and daily (2.5 mg) oral ibandronate. 4, 5 At 1 and 2 years, monthly ibandronate was noninferior to daily for increasing lumbar spine BMD (5.3%, 5.6% and 6.6% in the 50+50 mg, 100 mg and 150 mg regimens, respectively, vs 5.0% with daily at 2 years). At both time points, the 150 mg monthly dose was superior to the 2.5 mg daily dose (p%0.002). Pronounced decreases in bone resorption were reported with all regimens at 3 months, and were maintained for the duration of treatment. All regimens were well tolerated, with no disparity observed between the monthly and daily regimens. The clinical trial data confirms that once-monthly ibandronate is an effective and well tolerated treatment option. [1] [2] [3] However, with the introduction of a new treatment it is also important to consider the impact this has on one's own clinical decision making and individual patients. 4 In my department, a large number of postmenopausal women with osteoporosis are treated in clinical trials as well as in our outpatient clinic. We have participated in several clinical trials, including the BALTO II and MOTION studies, investigating the efficacy and safety of ibandronate and patient's preference for once-monthly versus weekly bisphosphonate dosing schedules. Additionally, we have prescribed ibandronate to an increasing number of routine patients over the last 6 months. I will discuss a variety of patient cases, including those without prior experience of bisphosphonates and those with prior experience of daily and weekly medication that have successfully switched to oncemonthly ibandronate. 
SY8. OPTIONS WHEN ORAL DOSING IS UNSUITABLE: INTRAVENOUS BISPHOSPHONATES
Recker RR; Creighton University, Omaha, NE, USA v Ibandronate can be administered orally and by intravenous (i.v.) injection v i.v. ibandronate has been widely studied for the treatment of postmenopausal osteoporosis v Summary of i.v. ibandronate studies:
-Antifracture study of 0.5 mg and 1 mg injections a) suboptimal antifracture result, dose-dependent changes in bone turnover and bone mineral density -Efficacy study of 1 mg and 2 mg injections 2 a) confirmation that ineffective dose used in previous study -DIVA study -comparing daily oral with 2mg and 3mg injections 3 a) both i.v. regimens confirmed noninferior to oral regimen for increases in lumbar spine bone mineral density Prevalence of osteoporosis and related fractures will increase significantly by 2020, with 14 million individuals over the age of 50 anticipated to have osteoporosis and 47 million to have low bone mass. Although osteoporosis and associated fractures have been recognized as a significant public health problem, underdiagnosis and undertreatment are still common. Annual direct care expenditures as a result of fractures range from billion annually, and indirect costs such as lost productivity add billions to this figure.
While osteoporosis is less frequent in men than women, onethird of all hip fractures occur in men. Deaths among men over age 75 from hip fractures is 30% versus 9% in women of the same age. In elderly men, steroidal treatments, medications to prevent convulsions, lowered testosterone levels, excessive alcohol consumption, lack of calcium in diet, smoking, and several other factors may increase the rate of bone loss. Importantly, men are more apt to reject diagnosis and treatment of osteoporosis than females, thus remaining a difficult challenge for physicians.
Patients who suffer non-spine fractures represent one of the simplest high-risk groups to identify and target for osteoporosis disease intervention, because they will seek medical care for an injury. Recognizing nonvertebral fractures as a potential early clinical indication of osteoporosis and initiating appropriate steps for diagnosis and treatment could enhance the clinical management of this disease in the growing elderly population. Research into the cellular processes involved in osteoclastogenesis has characterized an essential cytokine system for osteoclast biology consisting of the cytokine, RANK ligand (RANKL), a cellular receptor, RANK, and a receptor antagonist, osteoprotegerin (OPG). RANK ligand stimulates osteoclast function via RANK, thereby enhancing bone resorption; OPG blocks RANKL and prevents bone resorption. Imbalances of this system have been implicated in the pathogenesis of various skeletal diseases characterized by enhanced osteoclastic activity and increased bone resorption, including osteoporosis, bone erosions in rheumatoid arthritis, and bone metastases.
This symposium will focus on the emergence of RANK ligand inhibition as a novel, potentially viable therapeutic approach in the management of bone diseases, which effectively addresses the gaps in bone loss therapy across the bone loss continuum. The program will offer an opportunity to discuss emerging data for investigational pharmacological agents that block the activity of RANK ligand, including RANKL vaccines and a fully human monoclonal antibody directed against human RANK ligand, which is in late stage clinical trials. The symposium will also survey currently available data on investigational compounds such as Src tyrosine kinase (STK) inhibitors and cathepsin K inhibitors that disrupt osteoclast signaling pathways or regulatory molecules in the RANK/RANKL/OPG system, as well as a sclerostin monoclonal antibody that may modulate osteoblast expressed OPG and RANKL levels with anabolic effects on bone.
Long-term Management of Osteoporosis: The Quest for Real-world Effectiveness Sponsor: NOVARTIS
SY11. NEW CHALLENGES IN OSTEOPOROSIS IN THE 21ST CENTURY
with osteoporosis, the management of this disease continues to pose significant challenges. The most commonly prescribed agents are the oral bisphosphonates, but compliance and persistence rates are typically quite low, which severely compromises the effectiveness of these therapies.
Another critical issue in the management of osteoporosis is the development and implementation of optimal screening, diagnostic, and treatment guidelines. The 2004 US Surgeon General Report on Bone Health and Osteoporosis concluded that although we now know much about osteoporosis, we are not currently making good use of this information. Osteoporosis continues to remain undetected in a large proportion of postmenopausal women. Bone mineral density (BMD) is an important component of osteoporosis detection, but other fracture risk factors should also be considered, as the majority of fractures occur in individuals with BMD levels above those considered diagnostic for osteoporosis. Even among patients who have been diagnosed with osteoporosis or who have had a fracture after menopause, fewer than half receive treatment. Although there are numerous clinical practice guidelines concerning osteoporosis, there is a lack of consistency among them, and levels of adherence to them are usually low. Some of the current available guidelines have significant gaps, such as appropriate treatment of patients with fragility fractures despite BMD above the intervention threshold. The 2002 Canadian guidelines were the first major evidence-based guidelines for osteoporosis, but other organizations have since followed their approach. In general, the International Osteoporosis Foundation guidelines often used in Europe are more conservative in their recommendations for treating patients, whereas the National Osteoporosis Foundation guidelines used in the US are more broad.
A new 10-year fracture probability algorithm is in development by the World Health Organization in collaboration with both IOF and NOF. This algorithm will more effectively identify patients at higher risk for fracture to allow for appropriate intervention. Improved implementation of newer screening, diagnostic, and treatment guidelines, along with the ongoing development of new therapies, should ideally be incorporated into a clearly defined standard of care for fracture prevention. Such a standard will be critical to reducing the human and economic costs of fractures in postmenopausal women and older men worldwide.
SY12. MECHANISMS AND UTILITY OF BISPHOSPHONATES IN METABOLIC BONE DISEASES

Papapoulos S; Department of Endocrinology & Metabolic Diseases, Leiden University Medical Center, Leiden, Netherlands
Bisphosphonates (BPs) are the most commonly prescribed agents for the treatment of skeletal disorders. The more potent nitrogencontaining bisphosphonates (N-BPs) inhibit bone resorption primarily by suppressing osteoclast activity through inhibition of farnesyl disphosphonate (FPP) synthase, a key enzyme in the mevalonate pathway. Inhibition of FPP synthase disrupts posttranslational modifications of key signaling proteins, thereby affecting cell proliferation and survival. The extent of inhibition of FPP synthase correlates well with the in vivo effect of N-BPs on bone resorption. Among N-BPs, zoledronic acid has a higher hydroxyapatite binding affinity and is a more potent inhibitor of FPP synthase, biochemical characteristics that may explain its high level of antiresorptive activity. Currently, mainly oral BPs are used for the treatment of osteoporosis, while IV BPs are widely used in oncology. IV BPs last longer and circumvent the gastrointestinal side effects associated with oral BPs. In addition, the newer, more potent IV BPs have the potential to improve compliance due to their long dosing interval.
BPs have an excellent long-term safety record, and are thus well-suited to the treatment of chronic bone diseases. IV BPs are associated with some side effects not observed with oral agents, including transient flu-like symptoms following initial infusions. Osteonecrosis of the jaw (ONJ) has been reported in cancer patients receiving IV BPs, but no causal relationship has been established. ONJ is very rare in patients with non-cancerous bone disorders, with no confirmed cases being reported in non-oncology trials with zoledronic acid 5 mg. In postmenopausal women, oral BPs normalize the elevated bone turnover rates to premenopausal levels, but no further suppression occurs during long-term use. Similar findings were observed with yearly infusions of zoledronic acid, with bone remodeling parameters remaining within the premenopausal range for up to 5 years of treatment. Furthermore, bone biopsy samples from patients who received a single infusion of zoledronic acid 5 mg for the treatment of Paget's disease showed normal bone formation.
The potent antiresorptive activity of N-BPs and their safety record make these agents prime candidates for long-term therapy for patients with metabolic bone diseases.
SY13. EFFICACY OF LONG-ACTING BISPHOSPHONATES IN METABOLIC BONE DISEASES
Adachi J; St Joseph Health Care, McMaster University, Hamilton, Ontario, Canada Paget's disease of bone and osteoporosis are the two most common metabolic bone diseases. Both have been successfully treated with bisphosphonates (BPs), with a growing body of data supporting the use of long lasting BPs for these conditions. In patients with Paget's disease, a single infusion of zoledronic acid 5 mg IV was found to be significantly more efficacious than oral risedronate 30 mg daily for 60 days as assessed by the proportion of patients achieving a therapeutic response and median time to response. In a long-term follow-up study of responders, 50% of risedronate treated patients lost their therapeutic response over a median follow-up period of 20 months, compared with 2% of zoledronic acid treated patients, suggesting that a single dose of zoledronic acid may have multiyear potential for maintaining remission in patients with Paget's disease. In addition, this study has been the first in Paget's disease patients to suggest benefits on health-related quality of life, as measured by components of the SF-36. The most common side effect of zoledronic acid 5 mg IV is acute phase reaction (transient, postinfusion, flu-like symptoms), which was observed in approximately 25% of patients in the Paget's studies. Onset occurs within 1 to 3 days after infusion, and symptoms usually resolve within 4 days. Symptoms may be mitigated by the use of acetaminophen (paracetamol) or NSAIDs.
Recent data have also been reported on the use of zoledronic acid 5 mg IV in women with postmenopausal osteoporosis, in a clinical study that assessed levels of urine N-telopeptide of type 1 collagen (NTX) and other markers of bone turnover in patients treated with zoledronic acid 5 mg IV or oral alendronate 70 mg weekly. Decreases in NTX have been shown to predict bone density improvements in postmenopausal women. Compared with alendronate, zoledronic acid 5 mg IV resulted in a more rapid onset of activity and significant reductions in NTX levels at all time points.
S359
Data from these recent studies indicate that long acting BPs may have significant potential in the treatment of metabolic bone diseases, and may provide advantages relative to currently available therapeutic options. The increased bone remodeling in women after menopause induces an imbalance between bone resorption and formation, leading to altered bone microarchitecture, decreased bone mass, and increased fracture risk. Current antiosteoporotic drugs decrease bone remodeling (both resorption and formation) or increase bone remodeling (more bone formation than resorption). Strontium ranelate is a newly developed antiosteoporotic drug that acts differently from other available treatments for osteoporosis. Strontium ranelate acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Preclinical studies showed that it enhances preosteoblastic cell replication, alkaline phosphatase activity, collagen synthesis, and mineralization in rat and mouse osteoblastic cell cultures. Conversely, strontium ranelate decreases bone resorption in rat and mouse organ culture systems and decreases the resorbing activity of rat and mouse osteoclastic cells. Additionally, recent data indicate that strontium ranelate reduces human preosteoclast differentiation into osteoclasts and increases apoptosis in isolated rabbit osteoclasts. In vivo, strontium ranelate increases bone formation and reduces bone resorption in normal mice, resulting in increased vertebral bone mass. In normal rats, strontium ranelate increases bone mass and improves microarchitecture and bone geometry, resulting in increased bone resistance. In the model of osteopenia induced by ovariectomy in adult rats, strontium ranelate decreases bone resorption but maintains bone formation at high levels showing the dissociation between bone resorption and formation, resulting in improved bone microarchitecture and increased bone mass and strength. In clinical trials (SOTI), bone marker evaluation showed that serum alkaline phosphatase levels increased whereas serum CTX levels simultaneously decreased in patients treated with Protelos versus placebo at all time-points. Histomorphometric analysis of bone biopsies obtained over 5 years in 89 untreated and 49 treated patients in these trials showed that bone resorption parameters tended to decrease (-6 to -14% for eroded surface, osteoclast surface, and osteoclast number) whereas osteoblast surface and mineral apposition rate increased significantly by 38% and 10%, respectively (P<0.05). These preclinical and clinical studies indicate that strontium ranelate acts by increasing bone formation and decreasing bone resorption, thus rebalancing bone turnover in favor of bone formation, an effect that results in increased bone mass and strength.
Redressing the Balance in Postmenopausal Osteoporosis
SY15. STRONTIUM RANELATE'S DUAL ACTION: A CLOSER LOOK
Russell RG; University of Oxford, Nuffield Orthopaedic CentreOxford, United Kingdom Strontium ranelate reduces both vertebral and nonvertebral fractures in women, including hip fractures, and is a new treatment for postmenopausal osteoporosis. Based on both experimental and clinical studies, there is evidence that it has a dual mode of action, both increasing bone formation and decreasing bone resorption. In this presentation we will review the evidence for these effects based on several new cellular studies.
Strontium (Sr) is a known agonist of the extracellular calciumsensing receptor (CaSR).
1,2 Recent data show that strontium ranelate significantly and dose-dependently increases osteoblast proliferation 2-to 3-fold, an effect partly involving CaSR 3 and upregulation of c-fos and erg-1 genes involved in the differentiation of osteoblasts. Results obtained in CaSR-null mice also suggest the additional involvement of a receptor distinct from CaSR. 4 Blockade of Sr-induced proliferation of murine calvaria primary osteoblasts by a selective cyclooxygenase inhibitor 5 suggests possible involvement of prostaglandins in anabolic actions.
Regarding bone resorption, mature rabbit osteoclasts express CaSR and Sr stimulates osteoclast apoptosis in vitro through the activation of the caspase cascade 6 , an effect apparently involving protein kinases C in contrast to calcium. 7 Another mode of osteoclast inhibition could be via Sr-induced synthesis of OPG (osteoprotegerin). Recently, an in vitro study performed on human primary osteoblasts and MG-63 cells showed that strontium ranelate is able to increase the expression of osteoprotegerin mRNA. 8 The negative regulation of osteoclast generation by strontium ranelate through stimulation of osteoblast OPG could potentially contribute to the dual mode of action of strontium ranelate at the cellular level. More work is needed to explore whether strontium ranelate acts only via these cellular effects or by other mechanisms.
Fractures commonly involve the spine and hip but 70-80% of all fractures arise at other sites. Over half of all fractures arise in individuals with osteopenia while women over 80 years contribute 25% of all fractures. Thus, a program for reducing fracture burden should assess drug efficacy against all fractures in a wide range of individuals.
In the SOTI study, among 1649 postmenopausal women with osteoporosis, strontium ranelate (SR) 2 g daily reduced the risk of vertebral fractures by 49% in the first year, and 41% over 3 years (RR=0.59; 95%CI, 0.48-0.73). In the TROPOS study, among 3640 patients with spine X-rays, 66.4% had no prevalent fracture; the risk of vertebral fracture was reduced by 45% (RR=0.55; 95%CI, 0.42-0.72) over 3 years. In those with at least one prevalent fracture, the risk of vertebral fracture was reduced by 32% (RR 0.68; 95% CI 0.53-0.85)).
For nonvertebral fractures, in TROPOS, the risk for all nonvertebral fractures was reduced by 16% (RR=0.84; 95%CI, 0.702-0.995; P=0.04). In a post hoc analysis of 1977 women at high risk of hip fracture (age R74 years, femoral neck BMD T-score %-2.4 according to NHANES), the risk of hip fracture was reduced by 36% (RR=0.64; 95%CI, 0.412-0.997, P=0.046).
For patients with osteopenia, in the preplanned pooling of data from SOTI/TROPOS, 409 patients had osteopenia with lumbar and/or femoral neck T-score between -1 and -2.5 SD and both T-scores less reduced than -2.5 SD; 57% had a prevalent fracture. SR reduced the risk for vertebral fracture by 56% over 3 years (RR =0.44; 95%CI, 0.22-0.87; P=0.015). In the 43% without a prevalent fracture, SR reduced the risk for vertebral fracture by 72% over 3 years (RR=0.28; 95%CI, 0.07-0.99; P=0.045).
In preplanned pooling of data of the 1488 women aged between 80-100 years in SOTI/TROPOS, the risk for vertebral fracture was reduced by 32% (P=0.013) while the risk for non-vertebral fracture was reduced by 31% over 3 years (RR=0.69; 95% CI, 0.52-0.92). Strontium ranelate has a broad anti-fracture efficacy in postmenopausal women.
SY17. MEETING THE NEEDS OF OSTEOPOROTIC PATIENTS
Boonen S; Leuven University Center for Metabolic Bone Diseases, Katholieke Universiteit Leuven, Belgium A staggering 40% of postmenopausal women may suffer at least one osteoporosis related fracture during their lifetime, both vertebral and nonvertebral fractures contributing to the burden of the disease.
Strontium ranelate appears to have an original dual mode of action, allowing strontium ranelate to be targeted to an uncoupling of bone formation and bone resorption in the remodeling process, thus acting on both aspects of osteoporosis. In double-blind, placebo-controlled studies in patients with postmenopausal osteoporosis, strontium ranelate was shown to be effective in reducing both vertebral and nonvertebral (including hip) fracture risks. A significant reduction in the relative risk of vertebral fractures was observed within the first year of treatment, indicating that strontium therapy has a rapid rate of onset of treatment effect. This rapid onset of action is important, because recent evidence indicates that among women who experienced a vertebral fracture, nearly 20% will have a further fracture within one year. Osteoporosis is not only a rapidly progressing disease, it is also a chronic disease with a need for long-term treatment in many, if not most, patients. Recent 5-year fracture data from double-blind studies support the concept that the antifracture efficacy of strontium ranelate is maintained over time with, again, continued reductions in the risks of both vertebral and nonvertebral fractures. In addition, strontium ranelate was shown to positively influence the well being of the patients by significantly preventing their height loss, increasing the number of patients free of back pain, and improving their quality of life.
Treatment efficacy with strontium ranelate has been documented across a wide range of patient profiles with different degrees of severity of the disease, with or without preexisting osteoporotic fractures and across different age ranges. Even in frail elderly women over the age of 80 with comorbidities, treatment with strontium ranelate continues to be safe and to reduce vertebral and nonvertebral fracture risk. The consistency of the fracture data across different patient profiles whatever their age and different fracture types, the timing of the treatment effects, and its safety profile support the use of strontium ranelate as an attractive treatment option across the postmenopausal osteoporosis continuum. Vertebral body compression fractures (VCFs) are extremely common, with an incidence of 700,000 per year in the US and 1.4 million in Europe. Only about 30-40% of VCFs come to medical attention. Traditionally, VCF management has been with pain medications and bedrest for acute fractures and antiresorptive therapy for long-term prevention of subsequent fractures. However, the consequences of bedrest are not benign, and prospective studies document substantial decrements in quality of life following clinically evident VCF. Whether painful or not, VCFs contribute to kyphotic spinal deformity and increase the risk of future fractures. Substantial evidence suggests kyphosis profoundly impacts health, quality of life and survival.
Beyond
The standard orthopedic approach to fracture management (reduction, fixation) is now being applied to VCFs. A large amount of literature documents positive outcomes and low complication rates with minimally invasive vertebral augmentation procedures such as vertebroplasty and kyphoplasty. In vertebroplasty, bone cement is injected into the VCF percutaneously. In balloon kyphoplasty, an inflatable balloon tamp (IBT) is introduced prior to cement delivery to restore lost height and correct angular deformity. Clinical literature supporting these procedures is primarily single-center retrospective or prospective case series. Two concurrently controlled, but nonrandomized, studies comparing balloon kyphoplasty to nonsurgical management provide very supportive evidence. To date, however, no randomized trials have been published to evaluate the safety and effectiveness of either vertebroplasty or balloon kyphoplasty.
The FREE (Fracture REduction Evaluation) study is a randomized controlled trial of balloon kyphoplasty vs. nonsurgical management for the treatment of VCFs. To date, 300 patients with VCFs associated with back pain, loss of vertebral body height and edema on MRI have been enrolled and treated. The primary study endpoint is the Physical Component Summary score of SF-36 with secondary endpoints including back pain by VAS, Roland Morris Disability Questionnaire, satisfaction, and health care utilization. All endpoints are assessed at 1, 3, 12 and 24 months of follow-up; deformity correction and maintenance of lost vertebral height restored are assessed at 3, 12 and 24 months. FREE is a landmark study that will provide the first, randomized trial comparing balloon kyphoplasty to nonsurgical management for the treatment of VCFs.
The objective of the symposium is to present the development of tibolone for the indications prevention and treatment of osteoporosis. Tibolone is a tissue selective compound with estrogenic like activity on bone, vagina and vasomotor symptom relief but does not display estrogenic activity in endometrium or breast tissue.
Robert Lindsay will discuss the state of the art of the management of osteoporosis in postmenopausal women and emerging new treatment options such as tibolone.
Antwan Ederveen will present the preclinical development of tibolone and will discuss the potential caveats using different animal and imaging models. He will also present the mechanism of action and the preclinical data about the effects of tibolone on bone quality and strength.
Chris Gallagher will present the tissue selective clinical profile of tibolone. The efficacy data on bone and relief of vasomotor symptoms will be presented and the THEBES trial addressing the safety of tibolone on the endometrium will be highlighted.
Pierre Delmas will present the design of the tibolone fracture rate trial (LIFT) including some of the baseline data. He will also present the results of the comparative trials of tibolone versus raloxifene (STEP trial).
